title: Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
abstract: BACKGROUND
  This study was designed to evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for monitoring the WHO grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ).
  
  
  METHODS
  This prospective study included adult patients with progressive LGG that was confirmed by magnetic resonance imaging (MRI). Temozolomide was administered at every 28 days. Response to TMZ was evaluated by monthly MRI examinations that included MRI with volumetric calculations and (1)H-MRS for assessing Cho/Cr and Cho/NAA ratios. Univariate, multivariate and receiver-operating characteristic statistical analyses were performed on the results.
  
  
  RESULTS
  A total of 21 LGGs from 31 patients were included in the study, and followed for at least n=14 months during treatment. A total of 18 (86%) patients experienced a decrease in tumour volume with a greater decrease of metabolic ratios. Subsequently, five (28%) of these tumours resumed growth despite the continuation of TMZ administration with an earlier increase of metabolic ratios of 2 months. Three (14%) patients did not show any volume or metabolic change. The evolutions of the metabolic ratios, mean(Cho/Cr)(n) and mean(Cho/NAA)(n), were significantly correlated over time (Spearman ρ=+0.95) and followed a logarithmic regression (P>0.001). The evolutions over time of metabolic ratios, mean(Cho/Cr)(n) and mean(Cho/NAA)(n), were significantly correlated with the evolution of the mean relative decrease of tumour volume, mean(ΔV(n)/V(o)), according to a linear regression (P<0.001) in the 'response/no relapse' patient group, and with the evolution of the mean tumour volume (meanV(n)), according to an exponential regression (P<0.001) in the 'response/relapse' patient group. The mean relative decrease of metabolic ratio, mean(Δ(Cho/Cr)(n)/(Cho/Cr)(o)), at n=3 months was predictive of tumour response over the 14 months of follow-up. The mean relative change between metabolic ratios, mean((Cho/NAA)(n)-(Cho/Cr)(n))/(Cho/NAA)(n), at n=4 months was predictive of tumour relapse with a significant cutoff of 0.046, a sensitivity of 60% and a specificity of 100% (P=0.004).
  
  
  CONCLUSIONS
  The (1)H-MRS profile changes more widely and rapidly than tumour volume during the response and relapse phases, and represents an early predictive factor of outcome over 14 months of follow-up. Thus, (1)H-MRS may be a promising, non-invasive tool for predicting and monitoring the clinical response to TMZ.
authors: Department of Neuroradiology, Pitié-Sapêtrière Hospital, Functional Imaging Laboratory, INSERM U678, UPMC University Paris 6, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. remy.guillevin@psl.aphp.fr
authors: R
authors: R
authors: Guillevin
authors: C
authors: C
authors: Menuel
authors: S
authors: S
authors: Taillibert
authors: L
authors: L
authors: Capelle
authors: R
authors: R
authors: Costalat
authors: L
authors: L
authors: Abud
authors: C
authors: C
authors: Habas
authors: G
authors: G
authors: De Marco
authors: K
authors: K
authors: Hoang-Xuan
authors: J
authors: J
authors: Chiras
authors: J-N
authors: JN
authors: Vallée
references: J Neurooncol. 2010 Mar;97(1):73-80
references: 19727562
references: Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8
references: 11550134
references: Cancer. 2000 Jun 15;88(12):2887
references: 10870076
references: J Neurosurg. 1996 Mar;84(3):449-58
references: 8609557
references: J Neurosurg. 2006 Jul;105(1):6-14
references: 16874886
references: Neuroradiology. 2006 Mar;48(3):150-9
references: 16470375
references: J Neurooncol. 2008 Apr;87(2):181-7
references: 18163185
references: J Neurol Sci. 2003 Dec 15;216(1):1-10
references: 14607296
references: J Neurosurg. 1997 Oct;87(4):516-24
references: 9322842
references: Life Sci. 1996;58(22):1929-35
references: 8637421
references: NMR Biomed. 1999 May;12(3):123-38
references: 10414947
references: Br J Cancer. 2004 Feb 23;90(4):781-6
references: 14970853
references: J Comput Assist Tomogr. 1990 Jul-Aug;14(4):497-504
references: 2164536
references: Ann Biol Clin (Paris). 2008 Mar-Apr;66(2):143-50
references: 18390424
references: J Neurosurg. 2005 Aug;103(2):256-66
references: 16175855
references: Semin Oncol. 1994 Apr;21(2):236-48
references: 8153667
references: J Clin Oncol. 2004 Aug 1;22(15):3133-8
references: 15284265
references: Ann Neurol. 2007 May;61(5):484-90
references: 17469128
references: Neurology. 1996 Jan;46(1):203-7
references: 8559376
references: Ann Oncol. 2003 Dec;14(12):1715-21
references: 14630674
references: J Neurooncol. 2004 Dec;70(3):279-80
references: 15662968
references: Semin Radiat Oncol. 2001 Apr;11(2):103-12
references: 11285548
references: Can J Neurol Sci. 2001 Aug;28(3):215-23
references: 11513339
references: AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12
references: 11290466